Investorideas.com

Get investor ideas from our AI, cannabis, cleantech, crypto, gaming, mining, sports podcasts - be a guest or sponsor: call 800 665 0411


Share on StockTwits

Investor Ideas Potcasts #602, Cannabis News and Stocks on the Move; (TSX: VLNS) (OTCQX: VLNCF), (TSX: HEXO) (NASDAQ: HEXO), (NEO: MEDI), (CSE: BHSC)

 

Delta, Kelowna, BC - September 1, 2021 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today's podcast edition of cannabis news and stocks to watch plus insight from thought leaders and experts.

Listen to the podcast:

https://www.investorideas.com/Audio/Podcasts/2021/090121-StocksToWatch.mp3

Investor Ideas Potcasts #602, Cannabis News and Stocks on the Move; (TSX: VLNS) (OTCQX: VLNCF), (TSX: HEXO) (NASDAQ: HEXO), (NEO: MEDI), (CSE: BHSC)

SHARE PODCAST:      

Hear Investor ideas cannabis potcast on iTunes

Hear the investor ideas potcast on Spotify

Today's podcast overview/transcript:

Good afternoon and welcome to another episode of Investorideas.com "Potcast" featuring cannabis news, stocks to watch as well as insights from thought leaders and experts.

In today's podcast we look at a few public and private company announcements.

BioHarvest Sciences Inc. (CSE: BHSC) announced that it has successfully scaled its Cannabis cells with trichomes production by a factor of 250x and it is now growing Cannabis in medium-scale bioreactors, paving the way for its next scale-up milestone, where it will reach industrial-scale production. The next milestone, combined with the drying and measurement standards being concurrently developed, would constitute the successful completion of the Company's Cannabis development program.

Moving to the medium-scale bioreactors stage is not only a critical milestone in the scale-up and the proof of the capability of the BioFarming technology to produce Cannabis biomass, but is also an integral part of the industrial process development itself. The next milestone of the development program is growing Cannabis trichomes in industrial size bioreactors.

"The R&D methodology and relentless efforts are paying off," said Dr. Yochi Hagay, CTO, and added, "We are happy to have reached such a critical milestone. The recently announced and proprietary development of the Amalgamated Trichomes Coral Structure (ATCS) has certainly enabled this scale-up progress. As described before, ATCS protects the Trichomes during the growth phase against the shear forces generated by the media fluid motion. Such motion is exacerbated as you increase the size of the bioreactor, and I am confident that ATCS will sustain the forces in the next size of bioreactors, which is the final industrial-scale step. I look forward to announcing the completion of the whole program soon."

The CEO, Ilan Sobel, said, "Our industry-leading plant cell biology team is on track to deliver on one of the most challenging plant biological missions of growing cells of Cannabis Trichomes in liquid media at an industrial scale. Completing this mission will pave the way to the commercialization of BioFarming based Cannabis and Hemp products, marking a major turning point for the mainstream adoption of Cannabis by the global food and health sectors. The ability to economically and sustainably produce consistent, clean and pure whole spectrum Cannabis is nothing short of a revolution for the industry."

Eitan Popper, Chairman of BHSC's board of advisors and former President and Co-Founder of MedReleaf, stated, "BHSC's R&D team is making meaningful progress every month in the commercial scale-up of their Cannabis production. It is important to note that the most challenging part of the scale-up process is the transition from lab/bench scale to small-scale bioreactors, and then to medium-scale bioreactors. We are eagerly looking forward to the next Cannabis milestone announcement, as we know that it will be meaningful."

KetamineOne Capital Limited (NEO: MEDI) (OTC: KONEF), a company focused on consolidating medical clinics and becoming a North American leader in mental health treatments, announced that it has reached a commercial agreement with Cognetivity Neurosciences Ltd. (CSE: CGN) (OTCQB: CGNSF) for Cognetivity's Integrated Cognitive Assessment to be deployed in Ketamine One's clinics across North America. The Company and Cognetivity have also entered into a non-binding letter of intent to collaborate on mental health assessments and plan on conducting clinical trials within Ketamine One's network of clinics.

Cognetivity is a technology company that has created a cognitive testing platform for use in medical, commercial and consumer environments. Pursuant to the terms of the Agreement, Ketamine One plans to deploy Cognetivity's ICA across its network clinics to enable the long-term monitoring of cognitive performance in patients with treatment-resistant depression and post-traumatic stress disorder ("PTSD"). The ICA offers numerous benefits to clinicians, particularly in comparison to traditional, pen-and-paper-based tests. A computerized assessment that takes five minutes, the ICA is user-friendly and exhibits no learning effect upon repeat testing, making it perfectly suited to long-term monitoring.

The ICA is also highly sensitive to small changes in cognitive performance and, owing to its computerized nature, is capable of supporting remote, self-administered testing. Assessing individuals' cognition over the course of their treatment will enable the measurement of treatment efficacy, while empowering patients to take charge of their wellbeing and providing clinicians with additional data to refine treatment and improve outcomes.

In addition to the ICA's deployment in Ketamine One's clinics, the LOI will see Cognetivity and Ketamine One collaborate on developing and validating next-generation mental health assessment tools to improve the lives of sufferers. The Company believes that Cognetivity offers a unique and technologically advanced assessment tool that can help standardize in clinic procedures and offer a powerful analytical element to Ketamine One's digital therapeutic platform.

It is widely accepted that there is vast potential for improvement in the treatment of such conditions. According to the WHO, mental health disorders account for 28% of the global burden of disability-adjusted life years among non-communicable diseases - more than cardiovascular disease or cancer. Every year, more than 12 billion working days are lost due to mental health conditions, costing the global economy US$16 trillion in economic output between 2011 and 2030. The estimated addressable market size for anxiety disorder and depression treatments is US$238 billion.

HEXO Corp. (TSX: HEXO) (NASDAQ: HEXO) and 48North Cannabis Corp. announced that they have completed the previously announced arrangement, pursuant to which HEXO has acquired all of the issued and outstanding common shares of 48North by way of a court-approved plan of arrangement under the Canada Business Corporations Act

Under the terms of the Arrangement, each former shareholder of 48North is now entitled to receive 0.02366 of a common share in the capital of HEXO for each 48North Share held immediately prior to the completion of the Arrangement. It is anticipated that the 48North Shares will be de-listed from the TSX Venture Exchange as of the close of trading on or about September 2, 2021.

In order to receive the Consideration, registered holders of 48North Shares will be required to deposit their share certificate(s) representing 48North Shares, together with a duly completed letter of transmittal, with TSX Trust Company, the depositary under the Arrangement. Shareholders whose 48North Shares are registered in the name of a broker, dealer, bank, trust company or other nominee should contact their nominee regarding the receipt of the Consideration.

Further information about the Arrangement is set forth in the materials prepared by 48North in respect of the special meeting of 48North Shareholders held on August 17, 2021 (the "Meeting"), which were mailed to 48North Shareholders and filed under 48North's profile on the System for Electronic Document Analysis and Retrieval (SEDAR) at www.sedar.com.

The Valens Company Inc. (TSX: VLNS) (OTCQX: VLNCF), a leading manufacturer of cannabis products, announced that it has completed a transaction to acquire Verse Cannabis including all of the Verse intellectual property. This acquisition, and Valens' recently announced agreement to acquire Citizen Stash Cannabis Corp., positions Valens as a top tier cannabis licensed producer in the Canadian industry by total provincial listings and market share.

Since launching in August 2020, Verse has emerged as a leading cannabis brand with a wide-ranging portfolio that spans all major product categories. Verse has been a pioneer in the value segment starting with its Tropic Lemon 510 thread vape cartridges (including one of the first 1.0g cartridges on the market) and continuing with the recent launch of BC God Bud 28g offering. Today, Verse boasts a number of innovative products in its portfolio such as the Sour Medley and Baked Apple Soft Chews, Double Chocolate Brownie, THC and CBD SoRSE-based drops and the Rapid Tropical Rush beverage to name a few. With over 90 provincial listings across 7 provinces and territories today, Verse offers a wide selection of high-quality products providing consumers an array of cannabis consumption experiences without the uncomfortably high price point. Valens aims to leverage Verse products as its lead value-focused offering within its brand portfolio.

Tyler Robson, Chief Executive Officer and Chair of the Board of The Valens Company, said, "The acquisitions of Verse and Citizen Stash were motivated by an underlying desire to become an ally to both our customers and consumers. We believe in creating best-in-class products that consumers deserve in the right way, without ever cutting corners. Whether it's medical or recreational, local or international, third-party owned brands or Valens owned brands, we're pursuing purity in extraction, formulation, product development and testing to bring the benefits of cannabis to the world. The expanded platform we have built at Valens is now positioned to better serve current and future customers and consumers through unique product offerings at attractive price points while maximizing shareholder value through Valens branded products."

Investor ideas reminds all listeners to read our disclaimers and disclosures on the Investorideas.com website and that this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment.

Learn more about our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp

Or www.potcasts.ca

To hear more Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.

The Investorideas.com podcasts are also available on iTunes (Apple Podcasts), Audible, Spotify, Tunein, Stitcher, Spreaker.com, iHeartRadio, Google Podcasts and most audio platforms available.

Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708

Investors can trade these stocks and other ideas on our site using our list of top stock trading apps including Robinhood, Acorn, Stash and others.

About Investorideas.com - News that Inspires Big Investing Ideas

Investorideas.com publishes breaking stock news, third party stock research, guest posts and original articles and podcasts in leading stock sectors. Learn about investing in stocks and get investor ideas in cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy, gaming and more. Investor Idea's original branded content includes podcasts and columns: Crypto Corner, Play by Play sports and stock news, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast, Cleantech and Climate Change, Exploring Mining, Betting on Gaming Stocks Podcast and the AI Eye Podcast.

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers.

Contact management and IR of each company directly regarding specific questions.

More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.

Learn more about sponsoring this podcast or be a guest and our other branded content opportunities at Investorideas.com

Follow us on Cannabis Social Media

https://www.facebook.com/Investorideaspotcasts/

https://twitter.com/MJInvestorIdeas

https://www.instagram.com/investorideas_potcast/

Download our Mobile App for iPhone and Android

Contact Investorideas.com

800-665-0411


Get more Cannabis Stock Investor Ideas - news, articles, podcasts and stock directories

Buy a cannabis guest post on Investorideas.com